| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | HER2 |
| Clinical data | |
| Pregnancy cat. | ? |
| Legal status | ? |
| Identifiers | |
| CAS number | 380610-27-5 |
| ATC code | None |
| UNII | K16AIQ8CTM |
| KEGG | D05446 |
| Chemical data | |
| Formula | ? |
| (what is this?) (verify) |
|
Pertuzumab (also called 2C4, trade name Omnitarg) is a monoclonal antibody. The first of its class in a line of agents called "HER dimerization inhibitors". By binding to HER2, it inhibits the dimerization of HER2 with other HER receptors, which is hypothesized to result in slowed tumor growth.[1] Pertuzumab is currently being developed by Genentech.
Early clinical trials of pertuzumab in prostate, breast, and ovarian cancers have been met with limited success.[2]
The combination of pertuzumab plus trastuzumab plus docetaxel, as compared with placebo plus trastuzumab plus docetaxel, when used as first-line treatment for HER2-positive metastatic breast cancer, significantly prolonged progression-free survival, with no increase in cardiac toxic effects.[3]
10.1056/NEJMoa1113216